• Part time CFO
  • Transaction Services
  • About us
  • Clients
  • Blog
  • Contact Us
  • EN
    • FR

Aqemia, the new generation pharmaceutical company raises 30 million euros.

15 Mar, 2023
Transaction services: 2CFinance completed financial due diligence of Aqemia.

French medtech company Aqemia has raised €30m ($33m) in a funding round led by Eurazeo, with participation from Largeventure (of BPIFrance) and Elaia. The start-up, founded in 2019 by Maximilien Levesque and Emmanuelle Martiano, uses its Launchpad platform, which combines theoretical physics with AI, to quickly identify effective drug candidates for a given disease. The platform has already been adopted by pharmaceutical giants such as Sanofi, Janssen, and Servier. The new funding will be used to further develop its proprietary research projects, particularly in oncology and immuno-oncology, and to improve the platform.

The funding round was supported by transaction services provider 2CFinance, which conducted Aqemia's financial due diligence. Eurazeo is a French investment company with €18.8bn of assets under management and a focus on mid-cap firms. BPIFrance is a public investment bank that supports French companies throughout their funding stages. Largeventure is one of its investment vehicles, focused on late-stage venture capital.

Aqemia's platform has the potential to significantly cut the time and cost of drug discovery. By using computational approaches to identify promising drug candidates, it can reduce the need for traditional lab-based testing. This approach has already borne fruit: last year, Aqemia identified a promising molecule for the treatment of tuberculosis in a matter of days. With further development, the platform could revolutionize drug discovery and bring new treatments to market more quickly.

The funding round is further evidence of the growing importance of AI in the pharmaceutical industry, as companies seek to leverage its power to accelerate drug discovery and development. This trend is likely to continue, as AI continues to produce impressive results in a wide range of applications.

Revenir à la page actualités
2CFinance Label B Corp

2CFinance est désormais certifiée B Corp

Par 2cfinance - 15 Mar 2023

2CFinance, entité de 2CGroup, devient au 16 avril 2025, Entreprise Certifiée B Corp . Qu’est-ce que la certification B Corp ? B Corp est un label indépendant et international, attribué par l’ONG B Lab. Il évalue les entreprises sur des critères rigoureux couvrant : Contrairement à une auto-déclaration ou un label produit, la certification repose […]

Read

Comment créer un Business Plan solide pour attirer les investisseurs ?

Par 2cfinance - 15 Mar 2023

Dans l’univers compétitif des start-ups et du capital-risque, la rédaction d’un business plan financier (BP) est d’une importance capitale, et ce bien avant les phases de due diligence. Ce document, loin d’être une simple formalité, doit être le fruit d’une réflexion stratégique minutieuse menée par les fondateurs. Pour optimiser les chances de réussite lors d’une […]

Read

Les apports du DAF Part Time dans le retournement d’entreprise

Par 2cfinance - 15 Mar 2023

Dans un environnement économique incertain, les start-ups et les PME peuvent se trouver confrontées à des crises de liquidité non anticipées ou à des difficultés financières. Face à ces situations, le recours aux Directeurs Administratifs et Financiers (DAF) part-time s’avère être une stratégie efficace pour anticiper les tensions de trésorerie, ajuster les prévisions et trouver […]

Read
+33 (0)1 45 80 10 64
20 Boulevard Montmartre, 75009 Paris
© 2025 - All rights reserved Legals